PSC Biotech announced recently that it plans to house its newly launched subsidiary BioTechnique at University Research Park and be fully operational next year.

According to a release, BioTechnique will manufacture high-potency sterile injections, such as those used against cancer, and will provide high quality deliverables at all stages of the process from early stage contract manufacturing to commercial production.

“We are looking forward to fostering strong working relationships with the local academic institutions to create synergies, collaborations and partnerships, and by being located close to the University of Wisconsin and the Madison Area Technical College, BioTechnique will be able to tap into the area’s technical and intellectual capabilities and be an incubator for jobs,” PSC Biotech CEO John Clapham said in a statement.

The Wisconsin Economic Development Corporation will provide a $1 million loan to help the Pomona, Calif.-based company purchase equipment for the facility. In exchange, PSC Biotech has agreed to create at least 103 full-time jobs at the facility by the end of 2017 and invest $11.5 million in the project.